Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Hypoxia-Inducible Factor-2α Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer
2008
Hypoxia Drives Breast Tumor Malignancy through a TET–TNFα–p38–MAPK Signaling Axis
2015
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Genetic evidence for a tumor suppressor role of HIF-2α
2005
Molecular mechanisms mediating metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer
2012
Hallmarks of Cancer: The Next Generation
2011 Standout
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m 6 A-demethylation of NANOG mRNA
2016 StandoutNobel
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Regulation of Type II Transmembrane Serine Proteinase TMPRSS6 by Hypoxia-inducible Factors
2010 StandoutNobel
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Triple-Negative Breast Cancer
2010 Standout
Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression
2013
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer
2007
Prognostic Factors in Breast Cancer
2000
The pre-metastatic niche: finding common ground
2013
EGFR Antagonists in Cancer Treatment
2008 Standout
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
2000
Vascular Endothelial Growth Factor Mediates Intracrine Survival in Human Breast Carcinoma Cells through Internally Expressed VEGFR1/FLT1
2007
Regulation of cancer cell metabolism by hypoxia-inducible factor 1
2008 StandoutNobel
Expression of Hypoxia‐Inducible Factor (HIF)‐1α and Vascular Endothelial Growth Factor (VEGF)‐D As Outcome Predictors in Resected Esophageal Squamous Cell Carcinoma
2008
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis
2012 StandoutNobel
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Maternal and child undernutrition and overweight in low-income and middle-income countries
2013 Standout
Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect
2016 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
The hypoxic tumor microenvironment: A driving force for breast cancer progression
2015 StandoutNobel
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Four-and-a-Half LIM Domain Proteins Inhibit Transactivation by Hypoxia-inducible Factor 1
2012 StandoutNobel
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Hypoxia in cancer: significance and impact on clinical outcome
2007 Standout
Obesity and pregnancy: clinical management of the obese gravida
2011
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Gene expression and hypoxia in breast cancer
2011
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Reassessment of Exosome Composition
2019 Standout
An “elite hacker”
2012
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data
2012
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Evaluation of HIF-1 inhibitors as anticancer agents
2007 StandoutNobel
Tumor Angiogenesis
2008 Standout
Emerging targeted agents in metastatic breast cancer
2013
LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling
2013 StandoutNature
Chaperone-mediated Autophagy Targets Hypoxia-inducible Factor-1α (HIF-1α) for Lysosomal Degradation
2013 StandoutNobel
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype
2014 StandoutNobel
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression
2007
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
2011 StandoutNobel
Basal-Like Breast Cancer: A Critical Review
2008
Role of Hypoxia-Inducible Factors in Breast Cancer Metastasis
2013 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
2013 StandoutNobel
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
2013
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
2012 StandoutNobel
Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors
2013
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
HIF‐1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome
2007
Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning
2012 StandoutNobel
Microvessel Density as a Prognostic Factor in Women with Breast Cancer
2004
Works of Pascal Bonnier being referenced
c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse
1992
A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays
2008
Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients
2005
Validation of an immunohistochemical signature predictive of 8‐year outcome for patients with breast carcinoma
2011
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype
2007
Epidermal growth factor receptor in breast cancer: Correlation of quantitative immunocytochemical assays to prognostic factors
1993
Hypoxia inducible factor 1α gene (HIF-1α) splice variants: potential prognostic biomarkers in breast cancer
2010
Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905)
2004
CD31/PECAM Automated and Quantitative Immunocytochemical Assays in Breast Carcinomas:Correlation With Patient Follow-up
1997
Maternal and anthropomorphic risk factors for shoulder dystocia
2006
Influence of pregnancy on the outcome of breast cancer: A case-control study
1997
Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays
2010
c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival
1997
Quantitative Immunocytochemical Assays on Frozen Sections ofp53:Correlation to the Follow-up of Patients With Breast Carcinomas
1996
Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival.
1997
[Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma].
2003
Tumor Neoangiogenesis by CD31 and CD105 Expression Evaluation in Breast Carcinoma Tissue Microarrays
2004
Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis
2007
Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: Correlation with long-term patient outcome
2004
Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma
2005